Synergy Pharma’s “Buy” Rating Reaffirmed at Cantor Fitzgerald (SGYP)
The analysts wrote, “DDW Late Breaker announcement is an important catalyst for SGYP: Synergy announced that it would present full study results from its Phase IIb/ III chronic constipation (CC) trial of plecanatide in a late-breaking clinical abstract at Digestive Disease Week (DDW) on Tuesday, May 21. The poster will be presented by a well-known key opinion leader, which should enhance plecanatide visibility amongst gastroenterologists. We view this news as an important catalyst for the stock.”
SGYP has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity raised their price target on shares of Synergy Pharma to $10.00 in a research note to investors on Wednesday, January 2nd. They now have a “positive” rating on the stock. Analysts at Aegis reiterated a “buy” rating on shares of Synergy Pharma in a research note to investors on Friday, December 28th. They now have a $25.00 price target on the stock.
Shares of Synergy Pharma (NASDAQ: SGYP) traded up 2.66% during mid-day trading on Friday, hitting $6.17. Synergy Pharma has a 52 week low of $2.98 and a 52 week high of $7.08. The stock’s 50-day moving average is currently $5.79. The company’s market cap is $407.9 million.
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.